Dr. Purav Thakkar is a Physician and MBA with 24+ years of experience in clinical research and pharmacovigilance, currently serving as Medical Director at SciMax CRO. He has hands-on expertise leading global pharmacovigilance, clinical development, and regulatory-compliant programs. 

As a senior leader in clinical research and pharmacovigilance, Dr. Thakkar has contributed extensively to global CROs and prominent Indian pharmaceutical companies, including Cadila Pharmaceuticals and Torrent Pharmaceuticals. He has overseen end-to-end pharmacovigilance delivery, audits, and regulatory oversight for the US, EU, and India, managing large cross-functional teams and multi-regional safety operations across concurrent clinical and PV programs. Dr. Thakkar’s extensive expertise encompasses the following areas: 

• Pharmacovigilance operations: ICSR medical review, case processing, narratives, signal management, aggregate reports, risk management, audits, and inspections. 

• Clinical development & safety strategy: Phase I–IV trials, BA/BE studies, ATMPs, biologics, vaccines, and global regulatory alignment (US FDA, EMA, DCGI). 

• Project & team leadership: End-to-end PV delivery, cross-functional team management, client oversight, quality systems, and process optimization. 

With 24+ years leading global pharmacovigilance and clinical research initiatives, Dr. Thakkar has worked across innovator, biologics, vaccines, generics, and ATMPs. 

He holds an MBBS and MBA, has authored 7 peer-reviewed publications, and was a speaker at DIA Europe on early risk profiling of CAR T-cell therapies. Dr. Thakkar is a Life Member of the Ahmedabad and Maninagar Medical Associations. 

Dr. Thakkar leads industry-oriented curriculum design in pharmacovigilance and clinical research, incorporating real-world case studies, regulatory scenarios, and practical safety workflows. He also mentors new joiners and enterprise teams.